InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,732.93
(
0.00%
)
US TECH 100
19,391.60
(
-0.12%
)
Dow Jones
42,208.22
(
0.00%
)
Brent Oil
73.31
(
-1.68%
)
Bitcoin
63,714.61
(
-0.86%
)
Post# of 253213
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120491
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: kei post# 217216

Friday, 02/16/2018 9:00:33 AM

Friday, February 16, 2018 9:00:33 AM

Post# of 253213
APRI -73%/PM on CRL for Vitaros ED crème:

https://finance.yahoo.com/news/apricus-biosciences-receives-complete-response-120101399.html

The CRL indicates that the FDA cannot approve the NDA for Vitaros in its present form, identifying deficiencies related to Chemistry, Manufacturing and Control ("CMC") and certain safety concerns specific to the 2.5% concentration of DDAIP.HCl contained in the current formulation.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up